Positive Association of US-FLI With the Severity of CAD
Recruiting · NCT06541132 · Observational (researchers observe without assigning treatment) · Lead sponsor: Chongqing Medical University
View the official record on ClinicalTrials.gov →Interventions studied
Observational study without human intervention
What this trial is about
As a multisystem disease, metabolic dysfunction-associated fatty liver disease (MAFLD) is closely linked to the onset and progression of coronary heart disease (CHD). Ultrasonographic fatty liver indicator (US-FLI) is a semi-quantitative tool for evaluating the degree of hepatic steatosis. Our study aims to explore the relationship between US-FLI based on MAFLD and the severity of CHD.
Who can take part
Age range
18 Years to 90 Years
Sex
All (male and female)
Healthy volunteers
Yes - healthy volunteers may be accepted
Phase
Not specified
Study type
Observational (researchers observe without assigning treatment)
Inclusion criteria
- Patients older than 18 years old
- Patients underwent ICA due to chest pain, chest tightness or other reasons in our hospital from August 2022 to December 2023 were included in our study
Exclusion criteria
- Incomplete clinical data
- previous coronary stent implantation
- no abdominal ultrasound examination
- poor ultrasound image quality
- congenital heart disease
- tumor
- thyroid diseases and infectious diseases
Where it is running
1 location listed.
- The Second Affiliated Hospital of Chongqing Medical University - Chongqing, Chongqing Municipality, China